Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50-100x109/L.
暂无分享，去创建一个
H. Kantarjian | S. Verstovsek | M. Talpaz | R. Silver | J. Prchal | C. Holmes | L. Leopold | M. Baer | W. Peng | L. Afrin | R. Lyons | E. Winton | J. Harvey | S. Hamburg | K. Jamieson | H. Terebelo | S. Erickson‐Viitanen | Michael A. Scola | Gregory L. Ortega | Peter O'Neill